University of Illinois at Chicago
Announcement of an Exempt Purchase
Advanced Accelerator Applications USA IncMelburn, NJ
- Amount: An estimated $2,850,000
- Terms: An estimated start date of 3/8/2023 through 3/7/2026
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Wednesday, February 22, 2023
The University awarded a contract for radiopharmaceuticals.
This radiopharmaceutical, lutetium Lu 177 dotatate, is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults. The Pluvicto Lu-177 is indicated for the treatment for patients with Prostate Specific Membrane Antigen (PSMA)-Positive metastatic castration- resistant prostate cancer.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) This vendor is the only supplier of a particular Radiopharmaceutical (Lu-177). The price is same across all hospitals in the USA. Without these radiopharmaceuticals, UIH will not be able to provide care for the patients and will lose revenue.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.
